New vaginal ring could protect against HIV for three months
NCT ID NCT03670355
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a vaginal ring that slowly releases the HIV drug tenofovir over 90 days. Researchers wanted to see if the ring is safe and delivers enough drug to the body. 49 healthy women took part, and the study measured drug levels in blood, vaginal fluid, and tissue. If it works, this ring could offer a more convenient HIV prevention option than daily pills.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tenofovir
What this could lead to
If successful, this could lead to a long-acting vaginal ring that women can use for HIV prevention, reducing the need for daily pills.
What could go wrong
This is an early phase 1 trial with only 49 participants, so it is too small to prove effectiveness. The ring may not provide enough protection or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35294, United States
-
Bridge HIV CRS
San Francisco, California, 94143, United States
-
University of Pittsburgh CRS
Pittsburgh, Pennsylvania, 15213, United States